Transurethral resection of bladder tumour (TURBT) is the main operation used to diagnose and remove bladder tumours. A rigid cystoscope is passed through the urethra under anaesthesia, and the tumour is resected from inside the bladder without a skin incision. The goal is to remove all visible tumour where safely possible and to obtain tissue deep enough to show whether cancer has invaded the bladder muscle. This distinction determines treatment. A TURBT can be curative for some low-risk tumours, but higher-risk non-muscle-invasive cancers usually need additional intravesical treatment, and muscle-invasive disease requires staging and a different treatment plan.

Why TURBT matters so much

The procedure is both treatment and staging. A superficial-looking tumour can contain high-grade or deeper disease. The pathology report after TURBT should describe histological type, grade, depth of invasion and whether detrusor muscle is present in the specimen and involved by cancer.

How is TURBT performed?

1. Spinal or general anaesthesia is given.
2. A rigid resectoscope is passed through the urethra into the bladder.
3. The surgeon maps the tumour location, number, size and appearance.
4. Visible tumour is resected, often in separate superficial and deep samples when appropriate.
5. The tumour base and surrounding suspicious areas are treated or biopsied as needed.
6. A catheter may be left temporarily, especially when resection is extensive or bleeding is significant.

Will I have a catheter?

Some patients can void without a catheter after a small TURBT, while others need one overnight or for a few days. Continuous bladder irrigation may be used if there is significant bleeding. The duration depends on tumour size, location, depth of resection and bleeding.

Immediate intravesical chemotherapy

For selected low- or intermediate-risk tumours, a single dose of intravesical chemotherapy may be placed in the bladder soon after TURBT to reduce recurrence risk. It is avoided when bladder perforation is suspected, resection is very extensive, or significant bleeding makes instillation unsafe.

What does the pathology report mean?

When is a second TURBT needed?

Repeat resection is commonly recommended when the first TURBT was incomplete, when high-grade T1 disease is found, or when adequate muscle was not included in the specimen in a context where understaging is a concern. A second TURBT can find residual tumour and occasionally reveal previously unrecognized muscle invasion.

Recovery after TURBT

Burning, urgency and blood-stained urine are common for several days and can recur after becoming clear as the resection site heals. Avoid strenuous activity and heavy lifting for the period advised by your surgeon, because exertion can restart bleeding. Return to work depends on the extent of resection and job demands.

Risks

• Bleeding requiring catheter irrigation or, rarely, repeat surgery/transfusion.
• Urinary infection.
• Bladder perforation, usually managed with prolonged catheter drainage but occasionally requiring intervention.
• Urinary retention from clots or swelling.
• Urethral injury or later stricture in a minority.

What happens on the day of TURBT?

TURBT is performed through a resectoscope passed through the urethra, so there is usually no skin incision. Under anaesthesia, the surgeon inspects the bladder, resects visible tumour and takes tissue deep enough to assess stage while avoiding unnecessary perforation. Large or multifocal tumours may require staged resection. Selected patients receive a single immediate intravesical chemotherapy instillation after surgery when perforation is not suspected and the tumour setting is appropriate.

A urinary catheter may be left temporarily, particularly after a larger resection or when bleeding is expected. Continuous bladder irrigation is sometimes used until the urine clears. Many patients go home the same day or after a short stay, but this varies with tumour size, bleeding, anaesthesia and medical conditions.

Why “muscle present in the specimen” matters

Bladder muscle — detrusor muscle — in the TURBT specimen helps the pathologist determine whether a tumour has reached the muscular wall. In higher-risk disease, absence of muscle can make staging less secure and can be one reason a repeat TURBT is recommended. The need for re-resection also depends on completeness of the first TURBT, stage, grade and whether high-grade T1 disease is present.

This is why a pathology report that simply says “bladder cancer” is not enough. Patients should know the stage, grade and whether adequate deep tissue was sampled.

Consultation checklist

• Cystoscopy report and imaging.
• Medication list, especially anticoagulants/antiplatelets.
• Urine culture if recently infected.
• Previous TURBT and pathology reports.
• Kidney-function tests and major medical conditions.
• After surgery: keep the full pathology report, not only “bladder cancer positive.”

FAQs

Related reading

• Cystoscopy for Bladder Cancer
• Low-Grade vs High-Grade Bladder Cancer
• Non-Muscle Invasive Bladder Cancer
• BCG Therapy for Bladder Cancer
• Follow-Up Cystoscopy After Bladder Cancer
• Repeat TURBT: Why Is a Second Surgery Sometimes Needed?
• Urologist in Latur

References

• European Association of Urology (EAU). EAU Guidelines on Non-Muscle-Invasive Bladder Cancer. 2026 edition https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer
• British Association of Urological Surgeons (BAUS). Transurethral resection of bladder tumour (TURBT) patient information https://www.baus.org.uk/
• National Cancer Institute. Bladder Cancer Treatment (PDQ®)–Patient Version https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq
• American Urological Association/SUO. Non-Muscle Invasive Bladder Cancer Guideline (2016; amended 2024) https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline